Aptevo Therapeutics INC Form 4 insider transactions

Zsolt Harsanyi, a Director of Aptevo Therapeutics Inc., reported multiple transactions in common stock on August 6, 2026.

Jeffrey G. Lamothe, President and CEO and a Director of Aptevo Therapeutics Inc., reported multiple transactions in common stock on August 6, 2026.

Daphne Taylor, SVP, CFO of Aptevo Therapeutics Inc., reported multiple transactions in common stock on August 6, 2026.

Soyoung Kwon, SVP, GC, BD & Corp Affairs of Aptevo Therapeutics Inc., reported multiple transactions in common stock on August 6, 2026.

Dirk Huebner, SVP, CMO of Aptevo Therapeutics Inc., reported multiple transactions in common stock on August 6, 2026.

Grady Grant Iii, a Director of Aptevo Therapeutics Inc., reported multiple transactions in common stock on August 6, 2026.

Marvin L White, Executive Chair and a Director of Aptevo Therapeutics Inc., reported multiple transactions in common stock on July 17, 2026.

Daniel Abdun-Nabi, a Director of Aptevo Therapeutics Inc., reported multiple transactions in common stock on August 6, 2026.

Barbara Lopez Kunz, a Director of Aptevo Therapeutics Inc., reported multiple transactions in common stock on August 6, 2026.

John Niederhuber, a Director of Aptevo Therapeutics Inc., reported multiple transactions in common stock on August 6, 2026.

Aptevo Therapeutics Inc. Director Grady Grant III acquired 13,513 shares of common stock at $1.49 per share, increasing his direct beneficial ownership.

Bank of America entities report their beneficial ownership in Aptevo Therapeutics has fallen below 10%, ending Section 16 reporting obligations.

Aptevo Therapeutics Inc. Director Daniel Abdun-Nabi was granted 7,200 Restricted Stock Units, vesting fully on the first anniversary of the grant date.

Aptevo Therapeutics Inc.'s SVP and CFO, Daphne Taylor, was granted 11,500 Restricted Stock Units, vesting fully on the first anniversary of the grant date.

Aptevo Therapeutics Inc. director Grady Grant III was granted 7,200 Restricted Stock Units, vesting on the first anniversary of the grant date.

Aptevo Therapeutics Inc. granted 11,500 Restricted Stock Units to SVP and Chief Medical Officer Dirk Huebner, vesting fully on the first anniversary of the grant date.

Aptevo Therapeutics Inc. director John Niederhuber was granted 7,200 Restricted Stock Units, vesting one year from the August 6, 2025 grant date.

Aptevo Therapeutics Inc. reports its Chief Operating Officer, Jeffrey G. Lamothe, was granted 17,300 Restricted Stock Units.

Aptevo Therapeutics Inc. President and CEO Marvin L. White was granted 30,000 Restricted Stock Units, vesting in August 2026.

Aptevo Therapeutics Inc. Director Barbara Lopez Kunz was granted 7,200 Restricted Stock Units, vesting in full on the first anniversary of the grant date.

Aptevo Therapeutics Inc. granted 11,500 Restricted Stock Units to SoYoung Kwon, SVP, GC, BD & Corp Affairs, vesting on the first anniversary of the August 6, 2025 grant date.

Aptevo Therapeutics Director Zsolt Harsanyi was granted 7,200 Restricted Stock Units, vesting on the first anniversary of the grant date.

Aptevo Therapeutics Inc. Director Zsolt Harsanyi is set to convert a restricted stock unit into one common share on July 17, 2025, following a significant stock split.

Aptevo Therapeutics Inc. Director Barbara Lopez Kunz converted 1 Restricted Stock Unit into common stock on July 17, 2025, following its vesting.

Aptevo Therapeutics Inc. Director Daniel Abdun-Nabi converted one post-split Restricted Stock Unit into a common share on July 17, 2025, following a grant made in July 2024.

Aptevo Therapeutics Inc. Director Grady Grant III acquired one share of common stock through the conversion of a restricted stock unit on July 17, 2025.

Aptevo Therapeutics Inc. Director John Niederhuber converted 1 post-split Restricted Stock Unit into common stock on July 17, 2025, following a grant made on July 17, 2024.

Aptevo Therapeutics' Chief Financial Officer, Daphne Taylor, acquired common stock through the scheduled vesting of restricted stock units.

SoYoung Kwon, SVP, GC, BD & Corp Affairs at Aptevo Therapeutics, reported the vesting of Restricted Stock Units.

Aptevo Therapeutics Inc.'s President and CEO, Marvin L. White, acquired 10 shares of common stock through the vesting of Restricted Stock Units, increasing his direct ownership to 12 shares.